Article

Interpretation of neovascular AMD anti-VEGF data varies

Results from studies of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration can be interpreted in a variety of ways, depending on the baseline bias of the individual.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Related Content
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial
Published: October 12th 2024 | Updated: October 11th 2024

First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial

Week in Review - October 5, 2024
October 13th 2024

Week in Review - October 5, 2024

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300
October 11th 2024

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300

EyePod: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
October 11th 2024

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa
October 10th 2024

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa

AAO 2024 meeting information not to miss
October 10th 2024

AAO 2024 meeting information not to miss

© 2024 MJH Life Sciences

All rights reserved.